Tessa Recognised in “Most Promising Off-The-Shelf Therapies” category at ACGTEA 2022

KUALA LUMPUR, Sept 15 (Bernama) -- Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company, has announced that TT11X, the company’s allogeneic “off-the-shelf” CD30.CAR EBVST cell therapy, has been recognised in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022.

According to a statement, the ACGTEA 2022 Awards were held in conjunction with the 6th Cell & Gene Therapy World Asia 2022.

“We are very excited to be recognised among the innovators in developing ‘off-the-shelf’ cell therapy technologies and greatly appreciate the ACGTEA 2022 award,” said Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics, Dr Ivan Horak.

“Allogeneic cell therapy technology has the potential to transform the accessibility and affordability of CAR-T, but toxicity concerns remain a key obstacle.

“Data from our ongoing Phase 1 trial of TT11X suggest that our CD30.CAR EBVST platform has the potential to overcome these toxicity challenges, including GVHD, while also eliciting promising signals of efficacy.”

TT11X is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.

This technology was developed following decades-long research by the company’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and researchers at Baylor College of Medicine, into the unique properties of virus specific T-cells (VSTs).

These highly specialised T cells have the ability to recognise and kill infected cells while activating other parts of the immune system for a coordinated response.

Allogeneic VSTs without any form of genetic modification have demonstrated a strong safety profile and efficacy in early trials with minimal risk of graft rejection and Graft vs Host Disease (GVHD).

More details at www.tessacell.com.

-- BERNAMA